JP2023538963A - 抗ｔｎｆ治療に対する応答を予測するための方法およびシステム - Google Patents

抗ｔｎｆ治療に対する応答を予測するための方法およびシステム Download PDF

Info

Publication number
JP2023538963A
JP2023538963A JP2023513939A JP2023513939A JP2023538963A JP 2023538963 A JP2023538963 A JP 2023538963A JP 2023513939 A JP2023513939 A JP 2023513939A JP 2023513939 A JP2023513939 A JP 2023513939A JP 2023538963 A JP2023538963 A JP 2023538963A
Authority
JP
Japan
Prior art keywords
gene expression
tnf
treatment
disease
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538963A5 (https=
Inventor
ジアシアン，スーザン
サントリーニ，マルク
シェーンブルナー，ナンシー
ジェイ． ジョンソン，キース
Original Assignee
サイファー メディシン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイファー メディシン コーポレーション filed Critical サイファー メディシン コーポレーション
Publication of JP2023538963A publication Critical patent/JP2023538963A/ja
Publication of JP2023538963A5 publication Critical patent/JP2023538963A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Databases & Information Systems (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
JP2023513939A 2020-09-01 2021-08-31 抗ｔｎｆ治療に対する応答を予測するための方法およびシステム Pending JP2023538963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073336P 2020-09-01 2020-09-01
US63/073,336 2020-09-01
PCT/US2021/048346 WO2022051245A2 (en) 2020-09-01 2021-08-31 Methods and systems for predicting response to anti-tnf therapies

Publications (2)

Publication Number Publication Date
JP2023538963A true JP2023538963A (ja) 2023-09-12
JP2023538963A5 JP2023538963A5 (https=) 2024-08-26

Family

ID=80492102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513939A Pending JP2023538963A (ja) 2020-09-01 2021-08-31 抗ｔｎｆ治療に対する応答を予測するための方法およびシステム

Country Status (11)

Country Link
US (1) US20230282367A1 (https=)
EP (1) EP4208256A4 (https=)
JP (1) JP2023538963A (https=)
KR (1) KR20240018404A (https=)
CN (1) CN117615780A (https=)
AU (1) AU2021336781A1 (https=)
CA (1) CA3191195A1 (https=)
GB (1) GB2616129A (https=)
IL (1) IL300978A (https=)
MX (1) MX2023002446A (https=)
WO (1) WO2022051245A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496324B2 (ja) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
WO2023150731A2 (en) * 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies
CN120015309B (zh) * 2025-01-14 2025-12-12 中国人民解放军军事科学院军事医学研究院 用于急性高原反应（ams）易感性分群的装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178546A1 (en) * 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150491A2 (en) * 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
US20100303813A1 (en) * 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
ES2445892T3 (es) * 2008-08-25 2014-03-05 Janssen Biotech, Inc. Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados
WO2015148809A1 (en) * 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US12105089B2 (en) * 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
EA202191354A1 (ru) * 2018-11-15 2021-08-11 Янссен Байотек, Инк. Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
GB2603294A (en) * 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178546A1 (en) * 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies

Also Published As

Publication number Publication date
KR20240018404A (ko) 2024-02-13
WO2022051245A2 (en) 2022-03-10
EP4208256A2 (en) 2023-07-12
US20230282367A1 (en) 2023-09-07
MX2023002446A (es) 2023-05-12
CN117615780A (zh) 2024-02-27
EP4208256A4 (en) 2024-09-25
GB202303624D0 (en) 2023-04-26
GB2616129A (en) 2023-08-30
WO2022051245A3 (en) 2022-04-14
CA3191195A1 (en) 2022-03-10
IL300978A (en) 2023-04-01
AU2021336781A1 (en) 2023-05-11
AU2021336781A9 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
US12525318B2 (en) Method of monitoring anti-TNF therapy in a subject suffering from rheumatoid arthritis based in part on a trained machine learning classifier
US11987620B2 (en) Methods of treating a subject with an alternative to anti-TNF therapy
US20230282367A1 (en) Methods and systems for predicting response to anti-tnf therapies
US20260057960A1 (en) Systems and methods for predicting response to anti-tnf therapies
US20250270307A1 (en) Methods of classifying and treating patients
EP4359567A1 (en) Methods and systems for therapy monitoring and trial design
CN117813402A (zh) 分类和治疗患者的方法
CA3212448A1 (en) Methods of classifying and treating patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323